JP2018501195A5 - - Google Patents

Download PDF

Info

Publication number
JP2018501195A5
JP2018501195A5 JP2017524040A JP2017524040A JP2018501195A5 JP 2018501195 A5 JP2018501195 A5 JP 2018501195A5 JP 2017524040 A JP2017524040 A JP 2017524040A JP 2017524040 A JP2017524040 A JP 2017524040A JP 2018501195 A5 JP2018501195 A5 JP 2018501195A5
Authority
JP
Japan
Prior art keywords
agent
myh
mes
group
functional variant
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017524040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018501195A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2015/093726 external-priority patent/WO2016070798A1/zh
Publication of JP2018501195A publication Critical patent/JP2018501195A/ja
Publication of JP2018501195A5 publication Critical patent/JP2018501195A5/ja
Pending legal-status Critical Current

Links

JP2017524040A 2014-11-03 2015-11-03 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物 Pending JP2018501195A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN201410610777.X 2014-11-03
CN201410610777 2014-11-03
CN201510021469.8 2015-01-15
CN201510021469 2015-01-15
PCT/CN2015/093726 WO2016070798A1 (zh) 2014-11-03 2015-11-03 一种抑制脂肪细胞分化和胰岛素耐受的药物

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2020126891A Division JP7227197B2 (ja) 2014-11-03 2020-07-27 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物

Publications (2)

Publication Number Publication Date
JP2018501195A JP2018501195A (ja) 2018-01-18
JP2018501195A5 true JP2018501195A5 (cg-RX-API-DMAC10.html) 2018-12-13

Family

ID=55908589

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017524040A Pending JP2018501195A (ja) 2014-11-03 2015-11-03 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物
JP2020126891A Active JP7227197B2 (ja) 2014-11-03 2020-07-27 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2020126891A Active JP7227197B2 (ja) 2014-11-03 2020-07-27 脂肪細胞分化およびインスリン抵抗性を阻害するための薬物

Country Status (7)

Country Link
US (2) US20180015148A1 (cg-RX-API-DMAC10.html)
EP (1) EP3246043A4 (cg-RX-API-DMAC10.html)
JP (2) JP2018501195A (cg-RX-API-DMAC10.html)
CN (2) CN107148277B (cg-RX-API-DMAC10.html)
AU (1) AU2015342324B2 (cg-RX-API-DMAC10.html)
CA (1) CA3003760A1 (cg-RX-API-DMAC10.html)
WO (1) WO2016070798A1 (cg-RX-API-DMAC10.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6896636B2 (ja) * 2015-02-13 2021-06-30 清華大学Ｔｓｉｎｇｈｕａ Ｕｎｉｖｅｒｓｉｔｙ 組換えタンパク質薬の分子設計
WO2018086603A1 (zh) 2016-11-10 2018-05-17 北京普罗吉生物科技发展有限公司 聚乙二醇化血管内皮抑制素类似物及其应用
US10276161B2 (en) 2016-12-27 2019-04-30 Google Llc Contextual hotwords

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69824750T2 (de) * 1997-10-31 2005-07-07 Children's Medical Center Corp., Boston Methoden zur regulierung der grösse und des wachstums von durchblutetem normalem gewebe
EP1497314A4 (en) * 2001-09-07 2007-10-10 Univ Texas COMPOSITIONS AND METHODS OF USE ON PEPTIDES AGAINST PLACENTA AND FAT FABRICS
US7524811B2 (en) * 2003-08-29 2009-04-28 Children's Medical Center Corporation Anti-angiogenic peptides from the N-terminus of endostatin
CN103083681A (zh) * 2006-01-20 2013-05-08 清华大学 一种治疗肿瘤的药物及其应用
CN101596320B (zh) * 2006-01-20 2013-01-09 清华大学 一种治疗肿瘤的药物及其应用
WO2009062174A1 (en) * 2007-11-08 2009-05-14 University Of Utah Research Foundation Use of angiogenesis antagonists in conditions of abnormal venous proliferation
CN101219206A (zh) * 2008-02-01 2008-07-16 山东先声麦得津生物制药有限公司 重组人血管内皮抑制素在制药中的应用
CN102698270B (zh) * 2011-03-28 2016-02-03 清华大学 一种增强靶细胞摄取治疗剂的方法和药物组合物
CA2830375A1 (en) * 2011-03-30 2012-10-04 Board Of Regents Of The University Of Texas System Methods and compositions for targeting adipose cells in mammals
CN117987505A (zh) * 2011-09-09 2024-05-07 清华大学 对atp结合位点进行突变的血管内皮抑制素突变体

Similar Documents

Publication Publication Date Title
JP2016540785A5 (cg-RX-API-DMAC10.html)
WO2017022962A8 (ko) Ripk 억제제를 유효성분으로 포함하는 면역질환의 예방 또는 치료용 조성물
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
JP2015078220A5 (cg-RX-API-DMAC10.html)
EP4632075A3 (en) Method for reducing immunogenicity of rna
JP2013520405A5 (cg-RX-API-DMAC10.html)
WO2015044292A8 (en) Gene therapy compositions for use in the prevention and/or treatment of non-alcoholic fatty liver disease
EA201270221A1 (ru) Лечение болезни крона с применением лаквинимода
JP2015057451A5 (cg-RX-API-DMAC10.html)
JP2017519739A5 (cg-RX-API-DMAC10.html)
FI3294345T3 (fi) Tpp1-formulaatioita ja menetelmiä cln2-taudin hoitamiseksi
JP2014198723A5 (cg-RX-API-DMAC10.html)
JP2016510326A5 (cg-RX-API-DMAC10.html)
CN110114083A (zh) 一种预防和治疗脂肪肝的方法
HRP20210780T1 (hr) Pripravci koji sadrže bakterijske sojeve
JP2018521007A5 (cg-RX-API-DMAC10.html)
WO2018234871A3 (en) COMPOSITIONS FOR DRUG DELIVERY AND METHODS OF USE
PH12015500653B1 (en) Combination drug comprising gemigliptin and metformin, and method for the preparation thereof
JP2018199643A5 (cg-RX-API-DMAC10.html)
JP2019500379A5 (cg-RX-API-DMAC10.html)
MX2019003470A (es) Composicion farmaceutica y metodo para el tratamiento de la enfermedad del higado graso no alcoholico.
CN109311893A (zh) 含有取代环戊基的吡咯并嘧啶化合物
JP2019529569A5 (cg-RX-API-DMAC10.html)
CN107148277A (zh) 一种抑制脂肪细胞分化和胰岛素耐受的药物
WO2015165964A8 (en) Treatment and prevention of alzheimer's disease (ad)